APO Research
Talk to an analyst

APO RESEARCH · REPORT

Viibryd (Vilazodone)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Viibryd (Vilazodone) Market Outlook and Growth Opportunities 2026

22 December 2025197 pages

Choose your research edition.

Industry ResearchViibryd (Vilazodone) Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Viibryd (Vilazodone) Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Viibryd (Vilazodone) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viibryd (Vilazodone) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Viibryd (Vilazodone) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Viibryd (Vilazodone) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Viibryd (Vilazodone) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Viibryd (Vilazodone) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Viibryd (Vilazodone) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Viibryd (Vilazodone) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Viibryd (Vilazodone) market include Clinical Data, Inc., Allergan plc (AbbVie Inc.) and Actavis Generics (Teva), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Viibryd (Vilazodone) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Viibryd (Vilazodone) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Viibryd (Vilazodone) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Viibryd (Vilazodone) market size, projected growth trends, production technologies, key applications, and end-use industries.

Viibryd (Vilazodone) Segment by Company

Clinical Data, Inc.

Allergan plc (AbbVie Inc.)

Actavis Generics (Teva)

Viibryd (Vilazodone) Segment by Type

10 mg

20 mg

40 mg

Viibryd (Vilazodone) Segment by Application

Major Depression

Anxiety

Others

Viibryd (Vilazodone) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Viibryd (Vilazodone) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Viibryd (Vilazodone) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Viibryd (Vilazodone) significant trends, drivers, influence factors in global and regions.

6. To analyze Viibryd (Vilazodone) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viibryd (Vilazodone) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viibryd (Vilazodone) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viibryd (Vilazodone).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Viibryd (Vilazodone) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Viibryd (Vilazodone) industry.

Chapter 3: Detailed analysis of Viibryd (Vilazodone) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Viibryd (Vilazodone) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Viibryd (Vilazodone) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Viibryd (Vilazodone) Industry Trends Table 2. Viibryd (Vilazodone) Industry Drivers Table 3. Viibryd (Vilazodone) Industry Opportunities and Challenges Table 4. Viibryd (Vilazodone) Industry Restraints Table 5. Global Viibryd (Vilazodone) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Viibryd (Vilazodone) Revenue Share by Company (2021-2026) Table 7. Global Viibryd (Vilazodone) Sales Volume by Company (k units) & (2021-2026) Table 8. Global Viibryd (Vilazodone) Sales Volume Share by Company (2021-2026) Table 9. Global Viibryd (Vilazodone) Average Price (US$/unit) of Company (2021-2026) Table 10. Global Viibryd (Vilazodone) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Viibryd (Vilazodone) Key Company Manufacturing Base & Headquarters Table 12. Global Viibryd (Vilazodone) Company, Product Type & Application Table 13. Global Viibryd (Vilazodone) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Viibryd (Vilazodone) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 10 mg Table 18. Significant Companies of 20 mg Table 19. Significant Companies of 40 mg Table 20. Global Viibryd (Vilazodone) Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Viibryd (Vilazodone) Sales Volume by Type (2021-2026) & (k units) Table 22. Global Viibryd (Vilazodone) Sales Volume by Type (2027-2032) & (k units) Table 23. Global Viibryd (Vilazodone) Sales Volume Share by Type (2021-2026) Table 24. Global Viibryd (Vilazodone) Sales Volume Share by Type (2027-2032) Table 25. Global Viibryd (Vilazodone) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Viibryd (Vilazodone) Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Viibryd (Vilazodone) Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Viibryd (Vilazodone) Sales Value Share by Type (2021-2026) Table 29. Global Viibryd (Vilazodone) Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Major Depression Table 31. Significant Companies of Anxiety Table 32. Significant Companies of Others Table 33. Global Viibryd (Vilazodone) Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Viibryd (Vilazodone) Sales Volume by Application (2021-2026) & (k units) Table 35. Global Viibryd (Vilazodone) Sales Volume by Application (2027-2032) & (k units) Table 36. Global Viibryd (Vilazodone) Sales Volume Share by Application (2021-2026) Table 37. Global Viibryd (Vilazodone) Sales Volume Share by Application (2027-2032) Table 38. Global Viibryd (Vilazodone) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Viibryd (Vilazodone) Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Viibryd (Vilazodone) Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Viibryd (Vilazodone) Sales Value Share by Application (2021-2026) Table 42. Global Viibryd (Vilazodone) Sales Value Share by Application (2027-2032) Table 43. Global Viibryd (Vilazodone) Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Viibryd (Vilazodone) Sales by Region (2021-2026) & (k units) Table 45. Global Viibryd (Vilazodone) Sales Market Share by Region (2021-2026) Table 46. Global Viibryd (Vilazodone) Sales by Region (2027-2032) & (k units) Table 47. Global Viibryd (Vilazodone) Sales Market Share by Region (2027-2032) Table 48. Global Viibryd (Vilazodone) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Viibryd (Vilazodone) Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Viibryd (Vilazodone) Sales Value Share by Region (2021-2026) Table 51. Global Viibryd (Vilazodone) Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Viibryd (Vilazodone) Sales Value Share by Region (2027-2032) Table 53. Global Viibryd (Vilazodone) Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Viibryd (Vilazodone) Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Viibryd (Vilazodone) Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Viibryd (Vilazodone) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Viibryd (Vilazodone) Sales by Country (2021-2026) & (k units) Table 58. Global Viibryd (Vilazodone) Sales Market Share by Country (2021-2026) Table 59. Global Viibryd (Vilazodone) Sales by Country (2027-2032) & (k units) Table 60. Global Viibryd (Vilazodone) Sales Market Share by Country (2027-2032) Table 61. Global Viibryd (Vilazodone) Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Viibryd (Vilazodone) Sales Value Market Share by Country (2021-2026) Table 63. Global Viibryd (Vilazodone) Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Viibryd (Vilazodone) Sales Value Market Share by Country (2027-2032) Table 65. Clinical Data, Inc. Company Information Table 66. Clinical Data, Inc. Business Overview Table 67. Clinical Data, Inc. Viibryd (Vilazodone) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Clinical Data, Inc. Viibryd (Vilazodone) Product Portfolio Table 69. Clinical Data, Inc. Recent Development Table 70. Allergan plc (AbbVie Inc.) Company Information Table 71. Allergan plc (AbbVie Inc.) Business Overview Table 72. Allergan plc (AbbVie Inc.) Viibryd (Vilazodone) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Allergan plc (AbbVie Inc.) Viibryd (Vilazodone) Product Portfolio Table 74. Allergan plc (AbbVie Inc.) Recent Development Table 75. Actavis Generics (Teva) Company Information Table 76. Actavis Generics (Teva) Business Overview Table 77. Actavis Generics (Teva) Viibryd (Vilazodone) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Actavis Generics (Teva) Viibryd (Vilazodone) Product Portfolio Table 79. Actavis Generics (Teva) Recent Development Table 80. Key Raw Materials Table 81. Raw Materials Key Suppliers Table 82. Viibryd (Vilazodone) Distributors List Table 83. Viibryd (Vilazodone) Customers List Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Viibryd (Vilazodone) Product Image Figure 2. Global Viibryd (Vilazodone) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Viibryd (Vilazodone) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Viibryd (Vilazodone) Sales (2021-2032) & (k units) Figure 5. Global Viibryd (Vilazodone) Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Viibryd (Vilazodone) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 10 mg Image Figure 10. 20 mg Image Figure 11. 40 mg Image Figure 12. Global Viibryd (Vilazodone) Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Viibryd (Vilazodone) Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Viibryd (Vilazodone) Sales Volume Share by Type (2021-2032) Figure 15. Global Viibryd (Vilazodone) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Viibryd (Vilazodone) Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Viibryd (Vilazodone) Sales Value Share by Type (2021-2032) Figure 18. Major Depression Image Figure 19. Anxiety Image Figure 20. Others Image Figure 21. Global Viibryd (Vilazodone) Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Viibryd (Vilazodone) Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Viibryd (Vilazodone) Sales Volume Share by Application (2021-2032) Figure 24. Global Viibryd (Vilazodone) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Viibryd (Vilazodone) Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Viibryd (Vilazodone) Sales Value Share by Application (2021-2032) Figure 27. Global Viibryd (Vilazodone) Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Viibryd (Vilazodone) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Viibryd (Vilazodone) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Viibryd (Vilazodone) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Viibryd (Vilazodone) Sales Value (2021-2032) & (US$ Million) Figure 32. North America Viibryd (Vilazodone) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Viibryd (Vilazodone) Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Viibryd (Vilazodone) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Viibryd (Vilazodone) Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Viibryd (Vilazodone) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Viibryd (Vilazodone) Sales Value (2021-2032) & (US$ Million) Figure 38. South America Viibryd (Vilazodone) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Viibryd (Vilazodone) Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Viibryd (Vilazodone) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Viibryd (Vilazodone) Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Viibryd (Vilazodone) Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 10 mg
  • 20 mg
  • 40 mg
Applications
  • Major Depression
  • Anxiety
  • Others
Companies covered
  • Clinical Data, Inc.
  • Allergan plc (AbbVie Inc.)
  • Actavis Generics (Teva)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Viibryd (Vilazodone) Sales Value (2021-2032)
  4. 1.2.2 Global Viibryd (Vilazodone) Sales Volume (2021-2032)
  5. 1.2.3 Global Viibryd (Vilazodone) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Viibryd (Vilazodone) Market Dynamics
  1. 2.1 Viibryd (Vilazodone) Industry Trends
  2. 2.2 Viibryd (Vilazodone) Industry Drivers
  3. 2.3 Viibryd (Vilazodone) Industry Opportunities and Challenges
  4. 2.4 Viibryd (Vilazodone) Industry Restraints
3 Viibryd (Vilazodone) Market by Company
  1. 3.1 Global Viibryd (Vilazodone) Company Revenue Ranking in 2025
  2. 3.2 Global Viibryd (Vilazodone) Revenue by Company (2021-2026)
  3. 3.3 Global Viibryd (Vilazodone) Sales Volume by Company (2021-2026)
  4. 3.4 Global Viibryd (Vilazodone) Average Price by Company (2021-2026)
  5. 3.5 Global Viibryd (Vilazodone) Company Ranking (2024-2026)
  6. 3.6 Global Viibryd (Vilazodone) Company Manufacturing Base and Headquarters
  7. 3.7 Global Viibryd (Vilazodone) Company Product Type and Application
  8. 3.8 Global Viibryd (Vilazodone) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Viibryd (Vilazodone) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Viibryd (Vilazodone) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Viibryd (Vilazodone) Market by Type
  1. 4.1 Viibryd (Vilazodone) Type Introduction
  2. 4.1.1 10 mg
  3. 4.1.2 20 mg
  4. 4.1.3 40 mg
  5. 4.2 Global Viibryd (Vilazodone) Sales Volume by Type
  6. 4.2.1 Global Viibryd (Vilazodone) Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Viibryd (Vilazodone) Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Viibryd (Vilazodone) Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Viibryd (Vilazodone) Sales Value by Type
  10. 4.3.1 Global Viibryd (Vilazodone) Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Viibryd (Vilazodone) Sales Value by Type (2021-2032)
  12. 4.3.3 Global Viibryd (Vilazodone) Sales Value Share by Type (2021-2032)
5 Viibryd (Vilazodone) Market by Application
  1. 5.1 Viibryd (Vilazodone) Application Introduction
  2. 5.1.1 Major Depression
  3. 5.1.2 Anxiety
  4. 5.1.3 Others
  5. 5.2 Global Viibryd (Vilazodone) Sales Volume by Application
  6. 5.2.1 Global Viibryd (Vilazodone) Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Viibryd (Vilazodone) Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Viibryd (Vilazodone) Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Viibryd (Vilazodone) Sales Value by Application
  10. 5.3.1 Global Viibryd (Vilazodone) Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Viibryd (Vilazodone) Sales Value by Application (2021-2032)
  12. 5.3.3 Global Viibryd (Vilazodone) Sales Value Share by Application (2021-2032)
6 Viibryd (Vilazodone) Regional Sales and Value Analysis
  1. 6.1 Global Viibryd (Vilazodone) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Viibryd (Vilazodone) Sales by Region (2021-2032)
  3. 6.2.1 Global Viibryd (Vilazodone) Sales by Region: 2021-2026
  4. 6.2.2 Global Viibryd (Vilazodone) Sales by Region (2027-2032)
  5. 6.3 Global Viibryd (Vilazodone) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Viibryd (Vilazodone) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Viibryd (Vilazodone) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Viibryd (Vilazodone) Sales Value by Region (2027-2032)
  9. 6.5 Global Viibryd (Vilazodone) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Viibryd (Vilazodone) Sales Value (2021-2032)
  12. 6.6.2 North America Viibryd (Vilazodone) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Viibryd (Vilazodone) Sales Value (2021-2032)
  15. 6.7.2 Europe Viibryd (Vilazodone) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Viibryd (Vilazodone) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Viibryd (Vilazodone) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Viibryd (Vilazodone) Sales Value (2021-2032)
  21. 6.9.2 South America Viibryd (Vilazodone) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Viibryd (Vilazodone) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Viibryd (Vilazodone) Sales Value Share by Country, 2025 VS 2032
7 Viibryd (Vilazodone) Country-level Sales and Value Analysis
  1. 7.1 Global Viibryd (Vilazodone) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Viibryd (Vilazodone) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Viibryd (Vilazodone) Sales by Country (2021-2032)
  4. 7.3.1 Global Viibryd (Vilazodone) Sales by Country (2021-2026)
  5. 7.3.2 Global Viibryd (Vilazodone) Sales by Country (2027-2032)
  6. 7.4 Global Viibryd (Vilazodone) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Viibryd (Vilazodone) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Viibryd (Vilazodone) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Viibryd (Vilazodone) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Viibryd (Vilazodone) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Viibryd (Vilazodone) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Clinical Data, Inc.
  2. 8.1.1 Clinical Data, Inc. Company Information
  3. 8.1.2 Clinical Data, Inc. Business Overview
  4. 8.1.3 Clinical Data, Inc. Viibryd (Vilazodone) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Clinical Data, Inc. Viibryd (Vilazodone) Product Portfolio
  6. 8.1.5 Clinical Data, Inc. Recent Developments
  7. 8.2 Allergan plc (AbbVie Inc.)
  8. 8.2.1 Allergan plc (AbbVie Inc.) Company Information
  9. 8.2.2 Allergan plc (AbbVie Inc.) Business Overview
  10. 8.2.3 Allergan plc (AbbVie Inc.) Viibryd (Vilazodone) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Allergan plc (AbbVie Inc.) Viibryd (Vilazodone) Product Portfolio
  12. 8.2.5 Allergan plc (AbbVie Inc.) Recent Developments
  13. 8.3 Actavis Generics (Teva)
  14. 8.3.1 Actavis Generics (Teva) Company Information
  15. 8.3.2 Actavis Generics (Teva) Business Overview
  16. 8.3.3 Actavis Generics (Teva) Viibryd (Vilazodone) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Actavis Generics (Teva) Viibryd (Vilazodone) Product Portfolio
  18. 8.3.5 Actavis Generics (Teva) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Viibryd (Vilazodone) Value Chain Analysis
  2. 9.1.1 Viibryd (Vilazodone) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Viibryd (Vilazodone) Sales Mode & Process
  6. 9.2 Viibryd (Vilazodone) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Viibryd (Vilazodone) Distributors
  9. 9.2.3 Viibryd (Vilazodone) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst